Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOXR0916 plus Atezolizumab in Cisplatin-Ineligible Urothelial Carcinoma
NCT03029832Phase 2Terminated
- Sponsor
- Genentech
- Start
- Apr 2017
- Primary completion
- Apr 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of Vonlerolizumab in urothelial carcinoma (UC), sponsored by Genentech. Started Apr 2017; status: terminated.
02
Drugs
Vonlerolizumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03029832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03029832.